Evaluating solutions to sponsorship bias

Journal of Medical Ethics

Volumn 34, Issue 8, 2008, Pages 627-630

  Doucet, M ^a   Sismondo, S ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONFLICT OF INTEREST; DRUG INDUSTRY; ECONOMICS; EPIDEMIOLOGY; ETHICS; EVALUATION; FINANCIAL MANAGEMENT; HUMAN; INTERPERSONAL COMMUNICATION; REGISTER;

BIAS (EPIDEMIOLOGY); CONFLICT OF INTEREST; DISCLOSURE; DRUG INDUSTRY; HUMANS; REGISTRIES; RESEARCH SUPPORT AS TOPIC;

EID: 55549112251     PISSN: 03066800     EISSN: 14734257     Source Type: Journal    
DOI: 10.1136/jme.2007.022467     Document Type: Review

References (38)

1. Bekelman J, Li Y, Gross C. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003;289:454-65.
2. Lexchin J, Bero L, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70.
3. Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials 2007;29:109-13
4. Als-Nielson B. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003;290:921-8.
5. American Medical Association. Influence of funding source on outcome, validity, and reliability of pharmaceutical research. 2004.
6. CONSORT. The CONSORT statement, 2006. See http://www.consort- statement.org/ (accessed 11 Apr 2008).
7. Finucane TCB. Association of funding and findings of pharmaceutical research at a meeting of a medical professional society. JAMA 2004;117:842-5.
8. Friedman LS, Richter ED. Relationship between conflict of interest and research results. J Gen Intern Med 2004;19:51.
9. Lexchin J. Implications of pharmaceutical funding on clinical research. Ann Pharmacother 2005;39:194-7.
10. Montori VM, Jaeschke R, Schuμnemann HJ, et al. Users' guide to detecting misleading claims in clinical research reports. BMJ 2004;329:1093-6.
11. Healy D, Cattell D. Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry 2003;183:22-7.
12. Sismondo S. Ghost-management: How much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med 2007. See http://medicine.plosjournals.org/perlserv/?request=get- document&doi=10.1371/journal.pmed.0040286&ct=1 (accessed 11 Apr 2008).
13. Lurie P, Almeida C, Stine N, et al. Financial conflict of interest disclosure and voting patterns at food and drug administration drug advisory committee meetings. JAMA 2006;295:1921-8.
14. Sismondo S. How pharmaceutical company funding affects trial results: causal structures and responses. Soc Sci Med 2008;66:1909-14.
15. Brown A, Kraft D, Schmitz S, et al. Association of industry sponsorship to published outcomes in gastrointestinal clinical research. Clin Gastroenterol Hepatol 2006;4:1445-51.
16. Montgomery J, Byerly M, Carmody T, et al. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials 2004;25:598-612.
17. Perlis CS, Harwood M, Perlis RH. Extent and impact of industry sponsorship conflicts of interest in dermatology research. J Am Acad Dermatol 2005;52:967-71.
18. Procyshyn RM, Chau A, Fortin P, et al. Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine. Can J Psychiat 2004;49:601-6.
19. Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA 2006;295:2270-6.
20. Angell M. The truth about drug companies: how they deceive us and what to do about it. New York: Random House, 2004.
21. Harris G. Medical marketing - treatment by incentive; as doctors write prescriptions, drug company writes a check. New York Times 27 June 2004.
22. Gardner W, Lidz CW, Hartwig KC. Authors' reports about research integrity problems in clinical trials. Contemp Clin Trials 2005;26:244-51.
23. Ranstam J, Buyse M, George SL, et al. Fraud in medical research: an international survey of biostatisticians. Control Clin Trials 2000;21:415-27.
24. Henry DA, Kerridge IH, Hill SR, et al. Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience. Med J Aust 2005;182:557-60.
25. Rochon PA, Gurwitz JH, Simms RW, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994;154:157-63.
26. Melander H, Ahlqvist-Rastad J, Meijer G, et al. Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003;326:1171-3.
27. Chin-Dusting J, Mizrahi J, Jennings G, et al. Finding improved medicines: the role of academic-industrial collaboration. Nat Rev Drug Discov 2005;4:891-7.
28. Gross C, Gupta A, Krumholz H. Disclosure of financial competing interests in randomised controlled trials: cross sectional review. BMJ 2003;183:161-6.
29. Perlis RH, Perlis CS, Wu Y, et al. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiat 2005;162:1957-60.
30. Stelfox H, Chua G, O'Rourke K, et al. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 1998;338:101-6.
31. Chaudhry S, Schroter S, Smith R, et al. Does declaration of competing interests affect readers' perceptions? A randomised trial. BMJ 2002;325:1391-2.
32. Cain DM, Loewenstein G, Moore DA. The dirt on coming clean: perverse effects of disclosing conflicts of interest. J Legal Stud 2005;34:1-25.
33. Heres S, Davis J, Maino KJ, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006;163:185-94.
34. Barden J, Derry S, McQuay H, et al. Bias from industry trial funding? A framework, a suggested approach, and a negative result. Pain 2006;121:207-18.
35. Djulbegovic B, Lacevic M, Cantor A, et al. The uncertainty principle and industry-sponsored research. Lancet 2000;356:635-8.
36. Schafer A. Biomedical conflicts of interest: a defence of the sequestration thesis-learning from the cases of Nancy Olivieri and David Healy. J Med Ethics 2004;30:8-24.
37. Stern JM, Simes JR. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997;315:640-5.
38. Hubbard T, Love J. A new trade framework for global healthcare R&D. PLoS Biol 2004;2:147-50. http://biology.plosjournals.org/ perlserv/?request=getdocument&doi=10.1371/journal.pbio.0020052 (accessed 12 May 2008).